Top

Published in:

Open Access 01-12-2015 | Research article

Helicobacter pylori infection is not associated with fatty liver disease including non-alcoholic fatty liver disease: a large-scale cross-sectional study in Japan

Authors: Kazuya Okushin, Yu Takahashi, Nobutake Yamamichi, Takeshi Shimamoto, Kenichiro Enooku, Hidetaka Fujinaga, Takeya Tsutsumi, Yoshizumi Shintani, Yoshiki Sakaguchi, Satoshi Ono, Shinya Kodashima, Mitsuhiro Fujishiro, Kyoji Moriya, Hiroshi Yotsuyanagi, Toru Mitsushima, Kazuhiko Koike

Published in: BMC Gastroenterology | Issue 1/2015

Abstract

Background

Fatty liver disease (FLD) including non-alcoholic fatty liver disease (NAFLD), a rapidly emerging and widely recognized liver disease today, is regarded as a hepatic manifestation of metabolic syndrome. Helicobacter pylori, one of the most common pathogens worldwide, has been reported to be associated with metabolic syndrome, but whether there is a direct association with FLD is as of yet unclear. The aim of this study was to clarify the association of FLD and NAFLD with causative background factors including Helicobacter pylori infection.

Methods

This was a cross-sectional study of Japanese adults who received medical checkups at a single medical center in 2010.Univariate and multivariate statistical analysis was performed to evaluate background factors for ultrasonography diagnosed FLD. Subjects free from alcohol influence were similarly analyzed for NAFLD.

Results

Of a total of 13,737 subjects, FLD was detected in 1,456 of 6,318 females (23.0 %) and 3,498 of 7,419 males (47.1%). Multivariable analyses revealed that body mass index (standardized coefficients of females and males (β-F/M) =143.5/102.5), serum ALT (β-F/M = 25.8/75.7), age (β-F/M = 34.3/17.2), and platelet count (β-F/M = 17.8/15.2) were positively associated with FLD in both genders. Of the 5,289 subjects free from alcohol influence, NAFLD was detected in 881 of 3,473 females (25.4%) and 921 of 1,816 males (50.7%). Body mass index (β-F/M = 113.3/55.3), serum ALT (β-F/M = 21.6/53.8), and platelet count (β-F/M = 13.8/11.8) were positively associated with NAFLD in both genders. Metabolic syndrome was positively associated with FLD and NAFLD only in males. In contrast, Helicobacter pylori infection status was neither associated with FLD nor NAFLD regardless of gender.

Conclusions

Body mass index, serum ALT and platelet count were significantly associated with FLD and NAFLD, whereas infection of Helicobacter pylori was not.

Available only for authorised users

Volzke H. Multicausality in fatty liver disease: is there a rationale to distinguish between alcoholic and non-alcoholic origin? World J Gastroenterol. 2012;18(27):3492–501.PubMedPubMedCentralCrossRef

Bellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut. 1997;41(6):845–50.PubMedPubMedCentralCrossRef

Bellentani S, Bedogni G, Miglioli L, Tiribelli C. The epidemiology of fatty liver. Eur J Gastroenterol Hepatol. 2004;16(11):1087–93.PubMedCrossRef

DoS Alves De Carvalho M, Coelho Cabral P, Kruze Grande De Arruda I, Goretti Pessoa De Araujo Burgos M, Da Silva Diniz A, Barros Pernambuco JR, et al. Risk factors associated with hepatic steatosis: a study in patients in the Northeast Brazil. Nutr Hosp. 2012;27(4):1344–50.

Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132(2):112–7.PubMedCrossRef

Lau K, Lorbeer R, Haring R, Schmidt CO, Wallaschofski H, Nauck M, et al. The association between fatty liver disease and blood pressure in a population-based prospective longitudinal study. J Hypertens. 2010;28(9):1829–35.PubMedCrossRef

Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatol (Baltimore, Md). 2012;55(6):2005–23.CrossRef

Sookoian S, Castano GO, Pirola CJ. Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: a meta-analysis of 43 175 individuals. Gut. 2014;63(3):530–2.PubMedCrossRef

Hamaguchi M, Kojima T, Ohbora A, Takeda N, Fukui M, Kato T. Protective effect of alcohol consumption for fatty liver but not metabolic syndrome. World J Gastroenterol. 2012;18(2):156–67.PubMedPubMedCentralCrossRef

10.

Liangpunsakul S, Chalasani N. What should we recommend to our patients with NAFLD regarding alcohol use? Am J Gastroenterol. 2012;107(7):976–8.PubMedPubMedCentralCrossRef

11.

Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol. 2003;38(10):954–61.PubMedCrossRef

12.

Ryan CK, Johnson LA, Germin BI, Marcos A. One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transpl. 2002;8(12):1114–22.PubMedCrossRef

13.

Nadalin S, Malago M, Valentin-Gamazo C, Testa G, Baba HA, Liu C, et al. Preoperative donor liver biopsy for adult living donor liver transplantation: risks and benefits. Liver Transpl. 2005;11(8):980–6.PubMedCrossRef

14.

Tran TT, Changsri C, Shackleton CR, Poordad FF, Nissen NN, Colquhoun S, et al. Living donor liver transplantation: histological abnormalities found on liver biopsies of apparently healthy potential donors. J Gastroenterol Hepatol. 2006;21(2):381–3.PubMedCrossRef

15.

Lee JY, Kim KM, Lee SG, Yu E, Lim YS, Lee HC, et al. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol. 2007;47(2):239–44.PubMedCrossRef

16.

Minervini MI, Ruppert K, Fontes P, Volpes R, Vizzini G, de Vera ME, et al. Liver biopsy findings from healthy potential living liver donors: reasons for disqualification, silent diseases and correlation with liver injury tests. J Hepatol. 2009;50(3):501–10.PubMedCrossRef

17.

Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274–85.PubMedCrossRef

18.

Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. In: Journal of hepatology. Volume 56. England: Published by Elsevier B.V; 2012. p. 1384–91.

19.

Rubinstein E, Lavine JE, Schwimmer JB. Hepatic, cardiovascular, and endocrine outcomes of the histological subphenotypes of nonalcoholic fatty liver disease. Semin Liver Dis. 2008;28(4):380–5.PubMedCrossRef

20.

de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008;48 Suppl 1:S104–12.PubMedCrossRef

21.

Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol. 2006;45(4):600–6.PubMedCrossRef

22.

Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30(5):1212–8.PubMedCrossRef

23.

Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917–23.PubMedCrossRef

24.

Frasinariu OE, Ceccarelli S, Alisi A, Moraru E, Nobili V. Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies. Dig Liver Dis. 2013;45(7):543–51.PubMedCrossRef

25.

Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482(7384):179–85.PubMedPubMedCentral

26.

Solga SF, Diehl AM. Gut flora-based therapy in liver disease? The liver cares about the gut. Hepatology (Baltimore, Md). 2004;39(5):1197–200.CrossRef

27.

Chassaing B, Etienne-Mesmin L, Gewirtz AT. Microbiota-liver axis in hepatic disease. Hepatology (Baltimore, Md). 2014;59(1):328–39.CrossRef

28.

Cover TL, Blaser MJ. Helicobacter pylori in health and disease. Gastroenterology. 2009;136(6):1863–73.PubMedPubMedCentralCrossRef

29.

Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut. 2012;61(5):646–64.PubMedCrossRef

30.

Matsuhisa T, Aftab H. Observation of gastric mucosa in Bangladesh, the country with the lowest incidence of gastric cancer, and Japan, the country with the highest incidence. Helicobacter. 2012;17(5):396–401.PubMedPubMedCentralCrossRef

31.

Takahashi Y, Yamamichi N, Shimamoto T, Mochizuki S, Fujishiro M, Takeuchi C, et al. Helicobacter pylori infection is positively associated with gallstones: a large-scale cross-sectional study in Japan. J Gastroenterol. 2014;49(5):882–9.PubMedCrossRef

32.

Patel P, Mendall MA, Carrington D, Strachan DP, Leatham E, Molineaux N, et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ. 1995;311(7007):711–4.PubMedPubMedCentralCrossRef

33.

Federman DG, Kirsner RS, Moriarty JP, Concato J. The effect of antibiotic therapy for patients infected with Helicobacter pylori who have chronic urticaria. J Am Acad Dermatol. 2003;49(5):861–4.PubMedCrossRef

34.

Maurer KJ, Ihrig MM, Rogers AB, Ng V, Bouchard G, Leonard MR, et al. Identification of cholelithogenic enterohepatic helicobacter species and their role in murine cholesterol gallstone formation. Gastroenterology. 2005;128(4):1023–33.PubMedCrossRef

35.

Naja F, Nasreddine L, Hwalla N, Moghames P, Shoaib H, Fatfat M, et al. Association of H. pylori infection with insulin resistance and metabolic syndrome among Lebanese adults. Helicobacter. 2012;17(6):444–51.PubMedCrossRef

36.

Cho I, Blaser MJ, Francois F, Mathew JP, Ye XY, Goldberg JD, Bini EJ: Helicobacter pylori and overweight status in the United States: data from the Third National Health and Nutrition Examination Survey. In: Am J Epidemiol. Volume 162, edn. United States; 2005: 579–584.

37.

Longo-Mbenza B, Nkondi Nsenga J, Vangu Ngoma D. Prevention of the metabolic syndrome insulin resistance and the atherosclerotic diseases in Africans infected by Helicobacter pylori infection and treated by antibiotics. Int J Cardiol. 2007;121(3):229–38.PubMedCrossRef

38.

Polyzos SA, Kountouras J, Zavos C, Deretzi G. Helicobacter pylori Infection and insulin resistance. Helicobacter. 2013;18(2):165–6.PubMedCrossRef

39.

Stergiopoulos C, Kountouras J, Daskalopoulou-Vlachoyianni E, Polyzos SA, Zavos C, Vlachoyiannis E, et al. Helicobacter pylori may play a role in both obstructive sleep apnea and metabolic syndrome. Sleep Med. 2012;13(2):212–3.PubMedCrossRef

40.

Shin DW, Kwon HT, Kang JM, Park JH, Choi HC, Park MS, et al. Association between metabolic syndrome and Helicobacter pylori infection diagnosed by histologic status and serological status. J Clin Gastroenterol. 2012;46(10):840–5.PubMedCrossRef

41.

Pietroiusti A, Diomedi M, Silvestrini M, Cupini LM, Luzzi I, Gomez-Miguel MJ, et al. Cytotoxin-associated gene-A–positive Helicobacter pylori strains are associated with atherosclerotic stroke. Circulation. 2002;106(5):580–4.PubMedCrossRef

42.

Gunji T, Matsuhashi N, Sato H, Fujibayashi K, Okumura M, Sasabe N, et al. Helicobacter pylori infection is significantly associated with metabolic syndrome in the Japanese population. Am J Gastroenterol. 2008;103(12):3005–10.PubMedCrossRef

43.

Polyzos SA, Kountouras J, Papatheodorou A, Patsiaoura K, Katsiki E, Zafeiriadou E, et al. Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism. 2013;62(1):121–6.PubMedCrossRef

44.

Danjo A, Yamaguchi K, Fujimoto K, Saitoh T, Inamori M, Ando T, et al. Comparison of endoscopic findings with symptom assessment systems (FSSG and QUEST) for gastroesophageal reflux disease in Japanese centres. J Gastroenterol Hepatol. 2009;24(4):633–8.PubMedCrossRef

45.

Kusano M, Shimoyama Y, Sugimoto S, Kawamura O, Maeda M, Minashi K, et al. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol. 2004;39(9):888–91.PubMedCrossRef

46.

Yamamichi N, Mochizuki S, Asada-Hirayama I, Mikami-Matsuda R, Shimamoto T, Konno-Shimizu M, et al. Lifestyle factors affecting gastroesophageal reflux disease symptoms: a cross-sectional study of healthy 19864 adults using FSSG scores. BMC Med. 2012;10:45.PubMedPubMedCentralCrossRef

47.

Shimamoto T, Yamamichi N, Kodashima S, Takahashi Y, Fujishiro M, Oka M, et al. No association of coffee consumption with gastric ulcer, duodenal ulcer, reflux esophagitis, and non-erosive reflux disease: a cross-sectional study of 8,013 healthy subjects in Japan. PLoS One. 2013;8(6):e65996.PubMedPubMedCentralCrossRef

48.

Minatsuki C, Yamamichi N, Shimamoto T, Kakimoto H, Takahashi Y, Fujishiro M, et al. Background factors of reflux esophagitis and non-erosive reflux disease: a cross-sectional study of 10,837 subjects in Japan. PLoS One. 2013;8(7):e69891.PubMedPubMedCentralCrossRef

49.

Yamamichi N, Hirano C, Shimamoto T, Minatsuki C, Takahashi Y, Nakayama C, et al. Associated factors of atrophic gastritis diagnosed by double-contrast upper gastrointestinal barium x-ray radiography: a cross-sectional study analyzing 6,901 healthy subjects in Japan. PLoS One. 2014;9(10):e111359.PubMedPubMedCentralCrossRef

50.

Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol. 2007;102(12):2708–15.PubMedCrossRef

51.

[Definition and the diagnostic standard for metabolic syndrome--Committee to Evaluate Diagnostic Standards for Metabolic Syndrome]. Nihon Naika Gakkai zasshi The Journal of the Japanese Society of Internal Medicine 2005, 94(4):794–809.

52.

Karcz WK, Krawczykowski D, Kuesters S, Marjanovic G, Kulemann B, Grobe H, et al. Influence of Sleeve Gastrectomy on NASH and Type 2 Diabetes Mellitus. J Obes. 2011;2011:765473.PubMedCrossRef

53.

Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011;33(5):525–40.PubMedCrossRef

54.

Inabe F, Takahashi E, Moriyama K, Negami M, Otsuka H. Risk assessment chart for predicting fatty liver in Japanese subjects. Tokai J Exp Clin Med. 2012;37(4):94–101.PubMed

55.

Becker U, Deis A, Sorensen TI, Gronbaek M, Borch-Johnsen K, Muller CF, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology. 1996;23(5):1025–9.PubMedCrossRef

56.

Ludwig J, McGill DB, Lindor KD. Review: nonalcoholic steatohepatitis. J Gastroenterol Hepatol. 1997;12(5):398–403.PubMedCrossRef

57.

Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009;360(26):2758–69.PubMedCrossRef

58.

Altamirano J, Bataller R. Alcoholic liver disease: pathogenesis and new targets for therapy. Nat Rev Gastroenterol Hepatol. 2011;8(9):491–501.PubMedCrossRef

59.

Mulhall BP, Ong JP, Younossi ZM. Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol. 2002;17(11):1136–43.PubMedCrossRef

60.

Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med. 1997;126(2):137–45.PubMedCrossRef

61.

Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123(1):134–40.PubMedCrossRef

62.

Festi D, Schiumerini R, Marzi L, Di Biase AR, Mandolesi D, Montrone L, et al. Review article: the diagnosis of non-alcoholic fatty liver disease – availability and accuracy of non-invasive methods. Aliment Pharmacol Ther. 2013;37(4):392–400.PubMedCrossRef

63.

Strauss S, Gavish E, Gottlieb P, Katsnelson L. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR Am J Roentgenol. 2007;189(6):W320–3.PubMedCrossRef

64.

Yamaji Y, Okamoto M, Yoshida H, Kawabe T, Wada R, Mitsushima T, et al. Cholelithiasis is a risk factor for colorectal adenoma. Am J Gastroenterol. 2008;103(11):2847–52.PubMedCrossRef

Title: Helicobacter pylori infection is not associated with fatty liver disease including non-alcoholic fatty liver disease: a large-scale cross-sectional study in Japan
Authors: Kazuya Okushin
Yu Takahashi
Nobutake Yamamichi
Takeshi Shimamoto
Kenichiro Enooku
Hidetaka Fujinaga
Takeya Tsutsumi
Yoshizumi Shintani
Yoshiki Sakaguchi
Satoshi Ono
Shinya Kodashima
Mitsuhiro Fujishiro
Kyoji Moriya
Hiroshi Yotsuyanagi
Toru Mitsushima
Kazuhiko Koike
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: BMC Gastroenterology / Issue 1/2015
Electronic ISSN: 1471-230X
DOI: https://doi.org/10.1186/s12876-015-0247-9

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Helicobacter pylori infection is not associated with fatty liver disease including non-alcoholic fatty liver disease: a large-scale cross-sectional study in Japan

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

A novel mutation within the lactase gene (LCT): the first report of congenital lactase deficiency diagnosed in Central Europe

Laparoscopic colonic resection for splenic flexure cancer: our experience

Massive pneumoretroperitoneum arising from emphysematous cholecystitis: a case report and the literature review

C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study

Desmoid tumors complicating Familial Adenomatous Polyposis: a meta-analysis mutation spectrum of affected individuals

Evaluation of dual-wavelength excitation autofluorescence imaging of colorectal tumours with a high-sensitivity CMOS imager: a cross-sectional study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page